Clinical Research Directory

Inclusion Criteria: * Fully understand the procedures of the clinical study and participate voluntarily with signed and dated written informed consent form, comply with the requirements of the study protocol. * Males and/or females at least 18 years old when signing the informed consent form. * Histologically confirmed AML (defined using WHO criteria 2016) with one of the following: Refractory to at least 1 cycle of induction chemotherapy. Relapsed after achieving remission with a prior therapy. * Subject is positive for FLT3 mutation in bone marrow or blood after completion of the subject's last interventional treatment. * Eastern cooperative oncology group performance status (ECOG) ≤2 at screening. * Life expectancy of at least 3 months. * Women of childbearing potential have a negative pregnancy test at baseline and are willing to employ an effective method of contraception for the entire duration of study treatment and 6 months after the last dose. Exclusion Criteria: * Known or suspected allergies to any of the investigational drug composition (HYML-122, lactose, hydroxypropyl cellulose, hyposubstituted hydroxypropyl cellulose, silicon dioxide, magnesium stearate, titanium dioxide and polyethylene glycol). * Medical history and surgical history excluded according to the protocol. * Any previous medical treatment history exclude from the protocol. * Abnormal laboratory results exclude from the protocol. * Combination of treatments and/or drugs required during the study period and cannot be discontinued that excluded from the protocol. * Alcohol abuse within 6 months prior to screening, defined as long-term drinking history, generally more than 5 years, equivalent to alcohol quantity ≥40g/d for men, ≥20g/d for women, or heavy drinking history within 2 weeks, equivalent to alcohol quantity ≥80g/d. alcohol volume (g) conversion formula=alcohol consumption (mL)\*alcohol content (%)\*0.8. * Abortion less than 30 days prior to screening, pregnant and lactating women (currently breast-feeding or less than one year after delivery although not breast-feeding), women of childbearing potential who are not guaranteed effective contraception during the study, planning pregnancy or donating eggs or sperm within 6 months after the last dose. * History of drug abuse or drug addicts. * Subjects may not be able to complete the study duo to poor compliance or other reasons, or unsuitable for the study by the investigator's judgment.